ArticleJournal of neurology2023
Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.
Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Neurologists' Views on the Management of Uncontrolled Epilepsy in Spain: A Preliminary Survey.Neurology and therapy · 2026Article
- The Role of Neurologists in the Management of Uncontrolled Epilepsy in Spain: Opportunities for Optimization.Neurology and therapy · 2026Review
- Economic burden and cost determinants of epilepsy in Georgia: A longitudinal cost-of-illness study.Epilepsia open · 2026Article
- Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?Neurology and therapy · 2026Article
- Perspectives on the burden of drug-resistant epilepsy and treatment priorities: Findings from a multistakeholder survey.Epilepsia open · 2026Article
- Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Observational
- Seizures beget more than seizures: Understanding the cellular, structural, individual and societal impact of seizures in epilepsy.Epilepsia open · 2025Review
- Short-term sick leave due to epilepsy in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT).Epilepsia open · 2025Article
- Composition and influencing factors of hospitalization expenses for epilepsy patients based on path analysis.International journal for equity in health · 2024Article
- Virus-Induced Epilepsy vs. Epilepsy Patients Acquiring Viral Infection: Unravelling the Complex Relationship for Precision Treatment.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy is a chronic brain disease characterized by recurrent seizures. We investigated real-world management of epilepsy across treatment lines in Spain, including healthcare resource use (HRU) and associated costs.
methodsThis was a retrospective study of real-life data from epilepsy patients prescribed antiseizure medication (ASM) between January 2016 and December 2021. Patients were grouped according to their line of treatment (1st, 2nd, 3rd and 4th +) during the recruitment period. Demographic and clinical characteristics, comorbidities and concomitant medications were analyzed during the baseline period (6 months before starting treatment line); antiepileptic treatments, concomitant medications, HRU and associated costs were analyzed during follow-up.
resultsThe study included 5006 patients. Treatment duration decreased as treatment lines progressed (mean ± SD progression time: 523.2 ± 279.1 days from 1st to 2nd line, 351.6 ± 194.4 days from 2nd to 3rd line; 272.7 ± 139.3 days from 3rd to 4th + line). Significant HRU differences were found with subsequent treatment lines, including an increase in hospital admissions and patients on sick leave. Mean (95% CI) adjusted total costs per patient were €2974/year (2773-3175) in the 1st line and €5735/year (5043-6428) in the 4th + line. There was an increase in adjusted direct and total costs with subsequent treatment lines; the mean difference in total costs between cohorts was €2761 (p < 0.001). The highest direct costs were associated with epilepsy medication, days at the hospital and specialist visits.
conclusionOur data revealed a progressive increase in the use of resources and associated costs across subsequent epilepsy treatment lines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.